PTC Therapeutics, Inc. (FRA:BH3)

Market Cap	5.25B +53.4%
Revenue (ttm)	882.96M -42.8%
Net Income	-33.60M
EPS	-0.41
Shares Out	n/a
PE Ratio	n/a
Forward PE	49.47
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	61.92
Previous Close	60.30
Day's Range	61.92 - 61.92
52-Week Range	41.40 - 77.02
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Jul 30, 2026

About PTC Therapeutics

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children....

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1998
• Employees: 991
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: BH3

Financial Performance

Financial numbers in USD

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 26, 2026

Data Sources Report a data error